Shares of OncoSec Medical Inc. (OTC: ONCS), a biopharmaceutical company engaged in the development of advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease, are gaining in trading today.
At last check, ONCS shares were trading 4.35% higher at $0.240 on volume of 181,745. The stock touched an intra-day high of $0.25. It has gained 9.09% in the last three trading sessions.
OncoSec last week announced that Dr. Adil Daud presented preliminary enrollment and safety data from the companyâ€™s ongoing Phase 2 metastatic melanoma clinical trial, OMS-I100. The data was presented at the Second European Post-Chicago Melanoma Meeting in Munich, Germany.
ONCS has completed approximately 50% enrollment for OMS-I100 so far. Based on existing data, no grade three or higher adverse events related to the treatment have been reported so far. Dr. Daud noted that interest in the study has been encouraging, and enrollment is expected to be completed by the end of this year.